Biotech News

GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome

GSK plc (GSK)GSK plc2026-06-25 13:46 ESTFDA / regulatory

GSK & XenoPort have resubmitted NDA to the FDA for approval of Solzira Extended Release Tablets, treatment of moderate-to-severe primary RLS

Open original release

Related news

GSK plc

GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NYSE
Sector
Biotechnology
Location
United States